Austar Lifesciences Limited
AULSF
$0.07
$0.0651,300.00%
OTC PK
| 12/31/2024 | 09/30/2024 | 06/30/2024 | 03/31/2024 | 12/31/2023 | |
|---|---|---|---|---|---|
| Revenue | -16.40% | -15.79% | -20.52% | -19.50% | -18.69% |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | -16.40% | -15.79% | -20.52% | -19.50% | -18.69% |
| Cost of Revenue | -17.43% | -13.24% | -17.19% | -15.94% | -14.95% |
| Gross Profit | -12.06% | -24.86% | -32.13% | -31.76% | -31.49% |
| SG&A Expenses | -29.57% | -22.20% | -18.02% | -4.72% | 9.46% |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -128.57% | -97.69% | -41.83% | -48.84% | -60.78% |
| Total Operating Expenses | -20.18% | -15.46% | -17.74% | -14.59% | -11.80% |
| Operating Income | 183.69% | -41.98% | -116.76% | -128.24% | -133.11% |
| Income Before Tax | 161.37% | -95.85% | -130.25% | -129.05% | -128.27% |
| Income Tax Expenses | 1,539.29% | 24.28% | -59.80% | -85.94% | -97.61% |
| Earnings from Continuing Operations | 138.84% | -117.00% | -141.54% | -136.75% | -134.06% |
| Earnings from Discontinued Operations | -- | 58.39% | -42.00% | -278.30% | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | 13.23% | 127.24% | 154.19% | 399.24% | -42.45% |
| Net Income | 114.03% | 56.93% | -2,231.76% | -313.02% | -228.02% |
| EBIT | 183.69% | -41.98% | -116.76% | -128.24% | -133.11% |
| EBITDA | 426.64% | 5.21% | -73.53% | -100.59% | -114.22% |
| EPS Basic | 114.15% | 57.41% | -2,175.00% | -312.07% | -227.98% |
| Normalized Basic EPS | 156.67% | -94.74% | -135.16% | -130.07% | -127.52% |
| EPS Diluted | 114.15% | 57.41% | -2,175.00% | -312.07% | -227.98% |
| Normalized Diluted EPS | 156.67% | -94.74% | -135.16% | -130.07% | -127.52% |
| Average Basic Shares Outstanding | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
| Average Diluted Shares Outstanding | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |